An advisory committee empaneled to recommend revisions to California’s formulary will take up the question of whether to add unique product identifiers to the drug list, an idea some system users said would have been more useful before the start of the year.
The six-member Pharmacy and Therapeutics Committee will discuss the structure and content of the Medical Treatment Utilization Schedule drug list, including unique pharmaceutical identifiers, at its inaugural meeting Sept. 26.
The MTUS list identifies drug ingredients that are “exempt” from prospective utilization r...
Comments